iocept, Inc., a cancer diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC), and circulating tumor DNA (ctDNA) tests utilizing a standard blood sample, or ‘liquid biopsy’. The company’s tests provide information to oncologists and other physicians that enable them to select the most appropriate treatment for their patients based on better, timelier and more-detailed data on the characteristics of tumors. The company’s OncoCEE-BR for breast cancer test, OncoCEE-LU for NSCLC test and OncoCEE-GA for gastric cancer test and its planned tests utilize its Cell Enrichment and Extraction, or CEE, technology for the enumeration and analysis of CTCs, and its CEE-Selector technology for the detection and analysis of ctDNA, each performed on a standard blood sample. The CEE technology is an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing real-time biomarker monitoring with a standard blood sample. The CEE-Selector technology enables mutation detection with enhanced sensitivity and specificity and is applicable to nucleic acid from CTCs or other sample types, such as blood plasma for ctDNA. Business Strategy The company plans to provide oncologists and other physicians with a straightforward means to profile and characterize their patients’ tumors on a real-time basis by analyzing CTCs and ctDNA found in standard blood draws. Research and Development The company incurred research and development expenses of $4.5 million, as of December 31, 2014. Intellectual Property Patents: As of December 31, 2014, the company owned eight issued U.S. patents, five pending U.S. patent applications and corresponding patents and patent applications internationally. In addition, as of December 31, 2014, the company co-owned two pending U.S. patent applications, as well as corresponding foreign patents and applications. Competition The company’s competitors include Janssen Diagnostics, LLC, Atossa Genetics, Alere (Adnagen), Illumina, Apocell, EPIC Sciences, Clearbridge Biomedics, Cynvenio Biosystems, Fluxion Biosciences, Guardant Health, RareCells, and Silicon Biosystems. Significant Events In June 2015, Biocept entered into a clinical collaboration with Sarah Cannon Research Institute. The company said that the collaboration aims to determine the clinical utility of detecting biomarkers present in circulating tumor cell (CTC) and circulating tumor DNA (ctDNA) in blood samples for estrogen positive (ER+) breast cancer patients using Biocept's OncoCEE technology. History Biocept, Inc. was founded in 1997 in California.
biocept inc (BIOC:NASDAQ CM)
5810 Nancy Ridge Drive
San Diego, CA 92121
|Atossa Genetics Inc||$0.96 USD||+0.0193|
|Fluidigm Corp||$21.17 USD||-0.70|
|Laboratory Corp of America Holdings||$122.21 USD||+0.50|
|Natera Inc||$18.04 USD||+0.04|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact BIOCEPT INC, please visit www.biocept.com. Company data is provided by Capital IQ. Please use this form to report any data issues.